| Disappointing Safety Data Rock Affymax; Hematide Path Unclear - BioWorld Online |
|
|
BioWorld OnlineInvestors hoping for a home run with the much-anticipated Phase III data of Hematide in chronic renal failure patients - including ...Affymax and Takeda Announce Phase 3 Trials Meet Primary Endpoints for ... read more |